These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

325 related articles for article (PubMed ID: 15961989)

  • 1. The use of tegaserod in critically ill patients with impaired gastric motility.
    Banh HL; MacLean C; Topp T; Hall R
    Clin Pharmacol Ther; 2005 Jun; 77(6):583-6. PubMed ID: 15961989
    [TBL] [Abstract][Full Text] [Related]  

  • 2. A clinical audit of the efficacy of tegaserod as a prokinetic agent in the intensive care unit.
    Stephens DP; Thomas JH; Collins SJ; Goldrick PB; Fowler S
    Crit Care Resusc; 2007 Jun; 9(2):148-50. PubMed ID: 17536982
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Tegaserod: a novel, selective 5-HT4 receptor partial agonist for irritable bowel syndrome.
    Beglinger C
    Int J Clin Pract; 2002; 56(1):47-51. PubMed ID: 11831835
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Effect of tegaserod on gut transit in male and female subjects.
    Degen L; Petrig C; Studer D; Schroller S; Beglinger C
    Neurogastroenterol Motil; 2005 Dec; 17(6):821-6. PubMed ID: 16336497
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Effect of tegaserod on work and daily activity in irritable bowel syndrome with constipation.
    Reilly MC; Barghout V; McBurney CR; Niecko TE
    Aliment Pharmacol Ther; 2005 Sep; 22(5):373-80. PubMed ID: 16128674
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Management of diabetic gastroparesis.
    Mukhopadhyay P; Basu AK
    J Indian Med Assoc; 2005 Mar; 103(3):184, 186. PubMed ID: 16173296
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Prokinetic drugs for feed intolerance in critical illness: current and potential therapies.
    Deane AM; Fraser RJ; Chapman MJ
    Crit Care Resusc; 2009 Jun; 11(2):132-43. PubMed ID: 19485878
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Clinical trial: effects of tegaserod on gastric motor and sensory function in patients with functional dyspepsia.
    Thumshirn M; Fruehauf H; Stutz B; Tougas G; Salter J; Fried M
    Aliment Pharmacol Ther; 2007 Nov; 26(10):1399-407. PubMed ID: 17892526
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The problem of gastric atony.
    Woosley KP
    Clin Tech Small Anim Pract; 2004 Feb; 19(1):43-8. PubMed ID: 15025196
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Use of novel prokinetic agents to facilitate return of gastrointestinal motility in adult critically ill patients.
    Roberts DJ; Banh HL; Hall RI
    Curr Opin Crit Care; 2006 Aug; 12(4):295-302. PubMed ID: 16810038
    [TBL] [Abstract][Full Text] [Related]  

  • 11. [Tegaserod in treatment of women with irritable bowel syndrome].
    Munck LK; Ainsworth MA
    Ugeskr Laeger; 2007 Jun; 169(23):2190-2. PubMed ID: 17592683
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Review article: tegaserod -- the global experience.
    Chey WD
    Aliment Pharmacol Ther; 2004 Nov; 20 Suppl 7():15-9. PubMed ID: 15521850
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Tegaserod, a 5-hydroxytryptamine type 4 receptor partial agonist, is devoid of electrocardiographic effects.
    Morganroth J; Rüegg PC; Dunger-Baldauf C; Appel-Dingemanse S; Bliesath H; Lefkowitz M
    Am J Gastroenterol; 2002 Sep; 97(9):2321-7. PubMed ID: 12358251
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Review article: tegaserod for chronic constipation.
    Johanson JF
    Aliment Pharmacol Ther; 2004 Nov; 20 Suppl 7():20-4. PubMed ID: 15521851
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Tegaserod for constipation-predominant irritable bowel syndrome.
    Kale-Pradhan PB; Wilhelm SM
    Pharmacotherapy; 2007 Feb; 27(2):267-77. PubMed ID: 17253916
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The use of erythromycin as a gastrointestinal prokinetic agent in adult critical care: benefits versus risks.
    Hawkyard CV; Koerner RJ
    J Antimicrob Chemother; 2007 Mar; 59(3):347-58. PubMed ID: 17289772
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Oral mitemcinal (GM-611), an erythromycin-derived prokinetic, accelerates normal and experimentally delayed gastric emptying in conscious dogs.
    Onoma M; Yogo K; Ozaki K; Kamei K; Akima M; Koga H; Itoh Z; Omura S; Takanashi H
    Clin Exp Pharmacol Physiol; 2008 Jan; 35(1):35-42. PubMed ID: 18047625
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Prokinetic therapy for feed intolerance in critical illness: one drug or two?
    Nguyen NQ; Chapman M; Fraser RJ; Bryant LK; Burgstad C; Holloway RH
    Crit Care Med; 2007 Nov; 35(11):2561-7. PubMed ID: 17828038
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Practicalities of nutrition support in the intensive care unit: the usefulness of gastric residual volume and prokinetic agents with enteral nutrition.
    Ridley EJ; Davies AR
    Nutrition; 2011 May; 27(5):509-12. PubMed ID: 21295944
    [TBL] [Abstract][Full Text] [Related]  

  • 20. [Study of erythromycin and metoclopramide in treatment of feeding intolerance of critically ill patients in intensive care unit].
    Lu NF; Zheng RQ; Lin H; Yang DG; Chen QH; Shao J; Yu JQ
    Zhongguo Wei Zhong Bing Ji Jiu Yi Xue; 2010 Jan; 22(1):36-9. PubMed ID: 20092709
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 17.